Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark Remedies

Circulite(R) Synergy(R) Pocket Circulatory Assist Device To Be Featured At ASAIO And PEDS Conference
CircuLite®, Inc. will be participating at the 2009 American Society for Artificial Internal Organs (ASAIO) conference in conjunction with the 5th International Conference on Pediatric Mechanical Circulatory Support Systems & Pediatric Cardiopulmonary Perfusion (PEDS) held May 28 - 30, 2009 in Dallas, with a booth display featuring it"s Synergy® Pocket Circulatory Assist Device. Synergy is the first micro-pump designed for long-term, partial circulatory support to improve the quality of life for a broad range of chronic heart failure patients.
generic viagra online
Magee-Womens Hospital Awarded For Achievements In Reducing Elective Induced Labor
Magee-Womens Hospital of UPMC recently won a first-place achievement award from the Hospital & Healthsystem Association of Pennsylvania (HAP) in patient safety for achievements in researching and improving the process for elective induction of a woman"s labor.
News of the day
Lilly Advances Second Alzheimer's Disease Treatment Candidate Into Late-Stage Testing By Launching Two Global Trials
Eli Lilly and Company (NYSE: LLY) announced it will begin enrolling patients this month in two separate but identical Phase III clinical trials of solanezumab(i), previously referred to as LY2062430, an anti-amyloid beta monoclonal antibody being investigated as a potential treatment to delay the progression of mild to moderate Alzheimer"s disease. The trials, called EXPEDITION and EXPEDITION 2, will each include a treatment period that lasts 18 months and are expected to enroll a total of 2,000 patients age 55 and over from 16 countries.
Cardiovascular

NPS RADAR Reviews Rivaroxaban - Oral Anticoagulant For Post-knee Replacement Surgery, Australia

Prescribers treating patients who have had total hip or knee replacement surgery can access an independent review of the oral anticoagulant rivaroxaban (Xarelto) in the August issue of NPS RADAR. NPS RADAR provides independent information about new medicines and changes to PBS listings to health professionals and is published to coincide with PBS updates, giving health professionals access to information when they need it. "GPs and pharmacists may see patients who have been initiated on rivaroxaban in hospital. They should be aware that rivaroxaban has only been evaluated for use in preventing deep vein thrombosis and pulmonary embolism after elective total hip or total knee replacement surgery," NPS senior adviser, quality use of medicines, Judith Mackson said. "Duration of the therapy is 14 days after knee replacement or 35 days after hip replacement and no longer. Some patients will need a GP prescription soon after discharge to cover the remaining duration of therapy. GPs will need to take into account the number of tablets the hospital has provided when selecting a suitable pack size and instructing the patient on how many tablets to take." Dose adjustment and titration, and monitoring of prothrombin time are not required. As with other anticoagulants, managing the risk of bleeding is a primary concern, and patients should be alert to possible signs of bleeding. "Prescribers should be aware that there are only small differences in efficacy and safety between rivaroxaban, low molecular weight heparins (Clexane and Fragmin), fondaparinux (Arixtra) and dabigatran (Pradaxa)," Ms Mackson said. Other topics covered in the latest edition of NPS RADAR include: - Hydromorphone prolonged-release tablets (Jurnista) for chronic severe disabling pain - Oxybutynin patch (Oxytrol) PBS listed as an alternative for overactive bladder - Update on PBS listings for Aboriginal peoples and Torres Strait Islanders - Sitagliptin with metformin - (Janumet) fixed-dose combination tablets PBS listed for type 2 diabetes mellitus - Risedronate (Actonel Once-a-month) and summary of anti-resorptive drug listings - Lanthanum (Fosrenol) tablets for adults with chronic kidney disease who are on dialysis http://www.nps.org.au/radar National Prescribing Service.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009